Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1676
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    51,244.32
    -439.52 (-0.85%)
     

  • CMC Crypto 200

    1,328.51
    -68.02 (-4.87%)
     

  • S&P 500

    5,112.00
    +63.58 (+1.26%)
     

  • DOW

    38,305.16
    +219.36 (+0.58%)
     

  • CRUDE OIL

    83.83
    +0.26 (+0.31%)
     

  • GOLD FUTURES

    2,348.20
    +5.70 (+0.24%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

BUZZ-AstraZeneca, Shire: drug competition fears knock shares

Reuters - UK Focus

** AstraZeneca (Swiss: AZN.SW - news) & Shire top UK blue-chip fallers, both down >2 pct, with analysts pointing to concerns over competitive positions of their respective drugs

** Astra hit by worries for sales of diabetes drug Onglyza after Merck (Other OTC: MKGAF - news) 's rival product Januvia shows clean bill of health in heart safety trial, with no increase in hospitalization for heart failure

** Earlier this month, US advisers said Onglyza & Takeda's Nesina had acceptable cardiovascular risk profiles but should carry information labels warning about heart failure risks

** US FDA decision to speed up review of Sanofi (NasdaqGM: GCVRZ - news) 's drug application for a new Fabry disease treatment is cited by one analyst as a possible negative for Shire (Xetra: S7E.DE - news) , given it would be a competitor for the co

ADVERTISEMENT

** Astra shares hit 2.5-wk lows, while Shire falls to 1-wk lows; GlaxoSmithKline (Other OTC: GLAXF - news) also under pressure, with sentiment in the sector also impacted by weakness from US peers

** Healthcare shares were some of US market's worst performers Monday after negative drug development news, reports criticizing high drug prices & a merger setback (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net; RM: ben.hirschler.thomsonreuters.com@reuters.net)